Mylan sues FDA over Celebrex copies; GSK scores EU marketing approval for COPD drug Incruse;

@FiercePharma: Why pay $100B for AstraZeneca? Let Pfizer's CEO count the reasons. Story | Follow @FiercePharma

@TracyStaton: Which Big Pharmas aren't making deal headlines (at least not yet)? Roche. Sanofi. J&J. Bristol-Myers. They're definitely outnumbered. | Follow @TracyStaton

@EricPFierce: Analyst says Bayer may sale plastics biz for $10B, use that to help fund deal for Merck OTC biz, or Zoetis. More | Follow @EricPFierce

@CarlyHFierce: ICYMI Friday... Experts: MERS vaccine is possible--but is it worth it? Article | Follow @CarlyHFierce

> Mylan ($MYL) has filed a lawsuit challenging the FDA's ruling on generic exclusivity for copies of Pfizer's ($PFE) Celebrex. Release

> GlaxoSmithKline ($GSK) has nabbed EU marketing approval for COPD treatment Incruse. Release

> The EU has recommended Bayer's Nexavar as a treatment for thyroid cancer. Release | Report

> A European Commission (EC) committee has endorsed new advice to reduce risks of impaired next-day driving after taking zolpidem-containing sleep aids like Ambien. Release

> Hypermarcas topped Brazil's pharmaceutical market last month and plans to expand its lead, execs said Monday. Report

> Wockhardt says a state regulator in India has lifted its drug ban on the company. More

Medical Device News

@FierceMedDev: Ariosa faces new patent pushback from rival Illumina. Story | Follow @FierceMedDev

@VarunSaxena2: RT from FierceMedicalDevices: Covidien quarterly sales up 3% to $2.6 billion. News | Follow @VarunSaxena2

@EmilyWFierce: New device from scientists @MESImedical could speed up the diagnosis for peripheral artery disease. More | Follow @EmilyWFierce

@MichaelGFierce: Imaging technique maps transdermal drug migration. Item | Follow @MichaelGFierce

> Orbimed, Novo back SI-Bone in $33M round for ortho tech. Story

> LabCorp slips as Medicare bites into revenue. More

> Sorin snags FDA approval for mitral device. Item

Biotech News

@FierceBiotech: Forest lands Furiex and expands GI business in $1.5B buyout deal. Story | Follow @FierceBiotech

@JohnCFierce: Pfizer and AstraZeneca spent a combined $11.5B on R&D last year, with mixed results. You can imagine how much of that would be cut after a merger. | Follow @JohnCFierce

@DamianFierce: Biotech is finally invited to the deal parade: Forest buying Furiex for $1.1B plus an eluxadoline-tied CVR. Release | Follow @DamianFierce

@EmilyMFierce: "We're at a very unique point in biology," says Johns Hopkins Medicine's Aravinda Chakrararti. Biology is complicated but not random. | Follow @EmilyMFierce

> Ignoring harsh lessons, Pfizer pursues $100B deal to buy struggling AstraZeneca. More

> OncoGenex, Teva flag a failed PhIII for prostate cancer drug. Article

CRO News

> Biogen and Quintiles ink a deep-seated deal to boost R&D efficiency. More

> Medidata's sales leap on spike in eClinical demand. Story

> Harlan picks a partner and expands in Southeast Asia. Article

> Catalent ticks up revenue as IPO pends. Report

> Big Pharma megadeals could spell trouble for CROs. News

> Bristol-Myers deepens CMO deal with Samsung. Item

Biotech IT News

> NIH lays out plan to work exome data into clinical research. More

> Wellcome Trust order helps Illumina blast past HiSeq X Ten sale forecasts. Story

> Y Combinator seeking software-enabled biotechs after raising funding limit. Article

> Feds fret over threat of healthcare data theft. News

> U.K. seeks help prioritizing $3.4B of Big Data projects. Report

> Google patents show plans for smart contact lenses. Item

And Finally... Companies are using the "Mighty Mice" drug discovery to make meds that could help rebuild muscle. More (sub. req.)

Suggested Articles

A group of senators is asking the FTC to take a careful look at pharma mergers given the cost of drugs in the U.S.

Life’s been tough for J&J's prostate cancer med Erleada in its battle with Pfizer-Astellas’ Xtandi. A new FDA nod could help level the playing field.…

Biogen plans to test its SMA drug Spinraza at a higher-than-approved dose as Novartis' rival gene therapy Zolgensma picks up traction.